Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

PRME


Fundamental

Company: Prime Medicine Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -1.66
Insider Own: 60.65%
Shs Outstand: 131.16M
Perf Week: 16.91%
Market Cap: 317.73M
Forward P/E: -
EPS next Y: -1.00
Insider Trans: 0.39%
Shs Float: 51.66M
Perf Month: 90.55%
Enterprise Value: 294.62M
PEG: -
EPS next Q: -0.36
Inst Own: 28.66%
Short Float: 35.77%
Perf Quarter: 21.00%
Income: -202.01M
P/S: 82.53
EPS this Y: 23.33%
Inst Trans: -6.35%
Short Ratio: 8.02
Perf Half Y: -13.88%
Sales: 3.85M
P/B: 2.97
EPS next Y Percentage: 20.83%
ROA: -63.17%
Short Interest: 18.48M
Perf YTD: -17.12%
Book/sh: 0.82
P/C: 2.20
EPS next 5Y: 18.30%
ROE: -115.21%
52W High: 6.75 -64.15%
Perf Year: -58.91%
Cash/sh: 1.10
P/FCF: -
EPS past 3/5Y: 4.95% -124.13%
ROIC: -91.32%
52W Low: 1.11 118.02%
Perf 3Y: -
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -69.34%
Volatility W: 15.93%
Volatility M: 12.66%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 76.53
EPS Y/Y TTM: 22.37%
Oper. Margin: -5369.68%
ATR (14): 0.25
Perf 10Y: -
Dividend Ex-Date: Sep 10, 2019
Quick Ratio: 4.78
Sales Y/Y TTM: 550.76%
Profit Margin: -5252.50%
RSI (14): 69.29
Recom: 1.73
Dividend Gr. 3/5Y: - -
Current Ratio: 4.78
EPS Q/Q: 9.47%
SMA20: 38.94%
Beta: 2.19
Target Price: 7.69
Payout: -
Debt/Eq: 1.13
Sales Q/Q: 146.02%
SMA50: 55.87%
Rel Volume: 2.38
Prev Close: 2.65
Employees: 214
LT Debt/Eq: 1.07
Earnings: May 08 BMO
SMA200: -8.31%
Avg Volume: 2.30M
Price: 2.42
IPO: Oct 20, 2022
Option/Short: Yes / Yes
EPS/Sales Surpr.: -27.59% -67.90%
Trades:
Volume: 5,476,002
Change: -8.68%

Technical:


Latest News:

Citigroup Upgrades Prime Medicine (PRME) - Nasdaq very bullish
PRME

Summary: Citigroup upgraded their outlook for Prime Medicine from Neutral to Buy with an analyst price forecast suggesting 114.11% upside. Various funds and institutions have reported positions in Prime Medicine, totaling 70,064K shares, with a bullish outlook indicated by the put/call ratio of 0.12.

Full article
2024-05-17T22:16:55Z